By the Top Tier Newswire AI Desk · September 2, 2026 at 11:04 AM ET · reviewed against 1 wire stories
ABSCI CORP (ABSI) is drawing unusual attention today. Our newswire has captured 1 story on ABSI across 1 source in the last 36 hours, with AI sentiment reading bullish (avg 73/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
ABSI stock is down 4.64% to $8.43 as of the latest trade. The decline comes amid mixed signals from the company and the broader market. While the stock opened higher and briefly touched a session high of $9.23, it reversed course and closed the session near the low end of its range. The move appears to be driven by a combination of earnings miss in the second quarter and broader market weakness affecting biotech names.
What Happened
Absci announced it will participate in upcoming investor conferences, a positive step for engagement with the market. However, the stock’s decline suggests investors are reacting to recent financial results. The company reported second-quarter earnings of $(0.21) per share, missing the estimated $(0.20), and revenue of $318,000, which fell short of the $1.169 million estimate. These results highlight the company’s ongoing challenges in scaling revenue and achieving profitability. Additionally, the stock is trading near the lower end of its 52-week range, which may be amplifying short-term pressure. The broader market also saw several biotech names decline, including AbCellera Biologics, which may have contributed to a sector-wide sell-off.
What The Data Shows
The stock opened at $8.85 and reached a high of $9.23 before declining to a session low of $8.36. Volume so far is 0.9 million shares, which is 0.2 times the 3-month daily average. This suggests limited participation in the move. The stock has traded between $2.24 and $12.05 over the past 52 weeks, with 23 fresh 52-week lows recorded on September 2. Despite recent insider buying, including a purchase by director Mary Szela on June 30, the stock has fallen from a recent 8-session high of $9.73 to its current price.
What To Watch
Absci has no upcoming earnings date scheduled. Investors should monitor coverage breadth and whether additional analysts revise their outlooks in response to the recent earnings miss.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
ABSI · Sep 2 session (5-min) · +0.68% vs prior close · updated 8:45 PM ETAI sentiment, last 36h · averaged over 1 story · 73/100 bullish
The headlines behind the move
Story flow · 1 story on the wire, last 36h · hover or tap a dot for the headline
1d agoYahoo FinanceBULLISH 73Product/PR
Baldness Drug Stocks like Veradermics (MANE) and Absci (ABSI) Are Chasing the Same Wall Street Magic as Ozempic
Bloomberg reported on August 29 that hair-loss drug stocks are surging as Wall Street bets on a new pharmaceutical goldmine following the GLP-1 weight-loss boom. Shares of Veradermics, Incorporated (NYSE:MANE) have climbed nearly 500% since its February 2026 initial public offering, while Absci Corporation (NASDAQ:ABSI)’s stock has more than doubled so far in 2026. Switzerland’s […]
Frequently asked questions
Why is ABSI stock moving today?
ABSCI CORP (ABSI) is drawing unusual attention today. Our newswire has captured 1 story on ABSI across 1 source in the last 36 hours, with AI sentiment reading bullish (avg 73/100). The most recent driver: "Baldness Drug Stocks like Veradermics (MANE) and Absci (ABSI) Are Chasing the Same Wall Street Magic as Ozempic" (Yahoo Finance).
Is ABSI a buy right now?
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of ABSI coverage reads 73/100 over 1 stories; treat it as a research signal and do your own diligence.
How fast does this page update?
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →